CD14 Protein (CD14) (AA 20-352)

Catalog No. ABIN2666875

This Recombinant CD14 protein is produced in CHO Cells.

Quick Overview for CD14 Protein (CD14) (AA 20-352) (ABIN2666875)

Target: CD14

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: CHO Cells

Application: Flow Cytometry (FACS)

Purity: > 95 % glycosylated, as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 20-352

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 100-400 ng/ml, corresponding to a specific activity of 1.0-2.5 x 104 units/mg, as determined by production of IL-8 from THP-1 cells trated with LPS (2 ng/ml) and CD14.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is 1X PBS, pH 7.2.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CD14

Alternative Name: CD14

Background: CD14 is a pattern recognition receptor important in innate immunity. CD14 exists in two forms, as a glycosylphosphatidylinositol-anchored protein on the surface of mononuclear cells and as a soluble protein in the blood. CD14 is shed from the surface of CD14-expressing cells, resulting in the soluble CD14 protein (sCD14). CD14 is down regulated from the cell membrane on stimulated monocytes by different factors such as LPS, IFNγ, PMA, calcium ionophore A 23187, and antibodies against CD14. CD14 can be released from the cells with GPI-phospholipase C and D (PLC/D). Membrane associated CD14 is a pro-inflammatory coreceptor for LPS, a characteristic constituent of the cell wall of Gram-negative bacteria. LPS interacts with LPS-binding protein (LBP) and CD14, and this complex interacts with TLR4, which subsequently induces inflammatory gene expression through NF- κB and mitogen-activated protein-kinase signaling in host cells. sCD14 enables responses to LPS by cells that do not express CD14 such as endothelial cells. In this sense, HUVEC cells respond to LPS by production of IL-6 and this responsiveness is serum dependent. Elevated levels of sCD14 has been detected in serum of patients with different diseases such as systemic lupus erythematosus, HIV infected patients, common variable immunodeficiency (CVID), and nonalcoholic fatty liver disease (NAFLD). Also, high levels of sCD14 has been associated with infectious diseases, including sepsis. In addition, it has been reported that sCD14 could be a potential biomarker for predicting the prognosis of breast invasive ductal carcinoma.

Molecular Weight: The 333 amino acid recombinant protein has a predicted molecular mass of approximately 35.8 kDa. The DTT-reduced and non-reduced glycosylated protein migrate at approximately 50-60 kDa and 40-55 kDa respectively by SDS-PAGE. The N-terminal amino acid is T

Pathways: TLR Signaling, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades